The utility of amnioinfusion in the prophylaxis of meconium-stained amniotic fluid infectious morbidity

Charles Adair, J. W. Weeks, G. Johnson, S. Burlison, S. London, D. F. Lewis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: To evaluate the utility of intrapartum amnioinfusion (AI) in reducing the infectious morbidity of patients with meconium-stained fluid (MSF). Previous studies have shown increased intraamniotic infection (IAI) and postpartum endometritis (PPE) rates in patients with MSF. Intraamniotic infection has been reduced with the prophylactic administration of ampicillin-sulbactam in MSF. Intraamniotic infection and PPE have been reduced with the use of AI in patients with clear fluid. No investigators have specifically examined the efficacy of AI in reducing meconium-stained, amniotic-fluid-associated infectious morbidity. Methods: A retrospective cohort study of all cases of MSF was conducted and included patients who delivered at Louisiana State University Medical Center-Shreveport during the one-year period from January to December 1996. Patients were identified from the perinatal database by the diagnosis code of MSF. The medical records were reviewed to determine the consistency of MSF and the presence or absence of infectious morbidity. Patient demographics, labor characteristics, and various risk factors for infection were sought. The main outcome measures were the occurrenee of clinical IAI or PPE. Statistical analysis included two-tailed unpaired t-test, X2, ANOVA, and Fisher exact test when appropriate. Results: Two hundred seventy-three medical records of patients with MSF were studied. One hundred twenty nine patients received AI, and 144 did not receive AI. No significant differences in demographics, labor characteristics, or outcome variables were noted between the two groups. The incidences of IAI were 18.6% and 24.3%, P = 0.13, in the AI and non-AI groups, respectively. Postpartum endometritis occurred in 22.5% of AI patients and 21.5% of non-AI patients, P = 0.97. Conclusions: The use of AI confers no benefit for the reduction of infectious morbidity in patients with MSF.

Original languageEnglish (US)
Pages (from-to)366-369
Number of pages4
JournalInfectious Diseases in Obstetrics and Gynecology
Volume5
Issue number6
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Meconium
Amniotic Fluid
Morbidity
Endometritis
Postpartum Period
Infection
Medical Records
Demography
Analysis of Variance
Cohort Studies
Retrospective Studies
Research Personnel
Outcome Assessment (Health Care)
Databases

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Obstetrics and Gynecology
  • Infectious Diseases

Cite this

The utility of amnioinfusion in the prophylaxis of meconium-stained amniotic fluid infectious morbidity. / Adair, Charles; Weeks, J. W.; Johnson, G.; Burlison, S.; London, S.; Lewis, D. F.

In: Infectious Diseases in Obstetrics and Gynecology, Vol. 5, No. 6, 01.01.1997, p. 366-369.

Research output: Contribution to journalArticle

Adair, Charles ; Weeks, J. W. ; Johnson, G. ; Burlison, S. ; London, S. ; Lewis, D. F. / The utility of amnioinfusion in the prophylaxis of meconium-stained amniotic fluid infectious morbidity. In: Infectious Diseases in Obstetrics and Gynecology. 1997 ; Vol. 5, No. 6. pp. 366-369.
@article{47177e5598194e80807b2929d1272756,
title = "The utility of amnioinfusion in the prophylaxis of meconium-stained amniotic fluid infectious morbidity",
abstract = "Objectives: To evaluate the utility of intrapartum amnioinfusion (AI) in reducing the infectious morbidity of patients with meconium-stained fluid (MSF). Previous studies have shown increased intraamniotic infection (IAI) and postpartum endometritis (PPE) rates in patients with MSF. Intraamniotic infection has been reduced with the prophylactic administration of ampicillin-sulbactam in MSF. Intraamniotic infection and PPE have been reduced with the use of AI in patients with clear fluid. No investigators have specifically examined the efficacy of AI in reducing meconium-stained, amniotic-fluid-associated infectious morbidity. Methods: A retrospective cohort study of all cases of MSF was conducted and included patients who delivered at Louisiana State University Medical Center-Shreveport during the one-year period from January to December 1996. Patients were identified from the perinatal database by the diagnosis code of MSF. The medical records were reviewed to determine the consistency of MSF and the presence or absence of infectious morbidity. Patient demographics, labor characteristics, and various risk factors for infection were sought. The main outcome measures were the occurrenee of clinical IAI or PPE. Statistical analysis included two-tailed unpaired t-test, X2, ANOVA, and Fisher exact test when appropriate. Results: Two hundred seventy-three medical records of patients with MSF were studied. One hundred twenty nine patients received AI, and 144 did not receive AI. No significant differences in demographics, labor characteristics, or outcome variables were noted between the two groups. The incidences of IAI were 18.6{\%} and 24.3{\%}, P = 0.13, in the AI and non-AI groups, respectively. Postpartum endometritis occurred in 22.5{\%} of AI patients and 21.5{\%} of non-AI patients, P = 0.97. Conclusions: The use of AI confers no benefit for the reduction of infectious morbidity in patients with MSF.",
author = "Charles Adair and Weeks, {J. W.} and G. Johnson and S. Burlison and S. London and Lewis, {D. F.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1002/(SICI)1098-0997(1997)5:6<366::AID-IDOG4>3.0.CO;2-S",
language = "English (US)",
volume = "5",
pages = "366--369",
journal = "Infectious Diseases in Obstetrics and Gynecology",
issn = "1064-7449",
publisher = "Hindawi Publishing Corporation",
number = "6",

}

TY - JOUR

T1 - The utility of amnioinfusion in the prophylaxis of meconium-stained amniotic fluid infectious morbidity

AU - Adair, Charles

AU - Weeks, J. W.

AU - Johnson, G.

AU - Burlison, S.

AU - London, S.

AU - Lewis, D. F.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Objectives: To evaluate the utility of intrapartum amnioinfusion (AI) in reducing the infectious morbidity of patients with meconium-stained fluid (MSF). Previous studies have shown increased intraamniotic infection (IAI) and postpartum endometritis (PPE) rates in patients with MSF. Intraamniotic infection has been reduced with the prophylactic administration of ampicillin-sulbactam in MSF. Intraamniotic infection and PPE have been reduced with the use of AI in patients with clear fluid. No investigators have specifically examined the efficacy of AI in reducing meconium-stained, amniotic-fluid-associated infectious morbidity. Methods: A retrospective cohort study of all cases of MSF was conducted and included patients who delivered at Louisiana State University Medical Center-Shreveport during the one-year period from January to December 1996. Patients were identified from the perinatal database by the diagnosis code of MSF. The medical records were reviewed to determine the consistency of MSF and the presence or absence of infectious morbidity. Patient demographics, labor characteristics, and various risk factors for infection were sought. The main outcome measures were the occurrenee of clinical IAI or PPE. Statistical analysis included two-tailed unpaired t-test, X2, ANOVA, and Fisher exact test when appropriate. Results: Two hundred seventy-three medical records of patients with MSF were studied. One hundred twenty nine patients received AI, and 144 did not receive AI. No significant differences in demographics, labor characteristics, or outcome variables were noted between the two groups. The incidences of IAI were 18.6% and 24.3%, P = 0.13, in the AI and non-AI groups, respectively. Postpartum endometritis occurred in 22.5% of AI patients and 21.5% of non-AI patients, P = 0.97. Conclusions: The use of AI confers no benefit for the reduction of infectious morbidity in patients with MSF.

AB - Objectives: To evaluate the utility of intrapartum amnioinfusion (AI) in reducing the infectious morbidity of patients with meconium-stained fluid (MSF). Previous studies have shown increased intraamniotic infection (IAI) and postpartum endometritis (PPE) rates in patients with MSF. Intraamniotic infection has been reduced with the prophylactic administration of ampicillin-sulbactam in MSF. Intraamniotic infection and PPE have been reduced with the use of AI in patients with clear fluid. No investigators have specifically examined the efficacy of AI in reducing meconium-stained, amniotic-fluid-associated infectious morbidity. Methods: A retrospective cohort study of all cases of MSF was conducted and included patients who delivered at Louisiana State University Medical Center-Shreveport during the one-year period from January to December 1996. Patients were identified from the perinatal database by the diagnosis code of MSF. The medical records were reviewed to determine the consistency of MSF and the presence or absence of infectious morbidity. Patient demographics, labor characteristics, and various risk factors for infection were sought. The main outcome measures were the occurrenee of clinical IAI or PPE. Statistical analysis included two-tailed unpaired t-test, X2, ANOVA, and Fisher exact test when appropriate. Results: Two hundred seventy-three medical records of patients with MSF were studied. One hundred twenty nine patients received AI, and 144 did not receive AI. No significant differences in demographics, labor characteristics, or outcome variables were noted between the two groups. The incidences of IAI were 18.6% and 24.3%, P = 0.13, in the AI and non-AI groups, respectively. Postpartum endometritis occurred in 22.5% of AI patients and 21.5% of non-AI patients, P = 0.97. Conclusions: The use of AI confers no benefit for the reduction of infectious morbidity in patients with MSF.

UR - http://www.scopus.com/inward/record.url?scp=0031448220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031448220&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-0997(1997)5:6<366::AID-IDOG4>3.0.CO;2-S

DO - 10.1002/(SICI)1098-0997(1997)5:6<366::AID-IDOG4>3.0.CO;2-S

M3 - Article

VL - 5

SP - 366

EP - 369

JO - Infectious Diseases in Obstetrics and Gynecology

JF - Infectious Diseases in Obstetrics and Gynecology

SN - 1064-7449

IS - 6

ER -